Clinical Trials

Lycia Therapeutics' oversubscribed $75M Series D validates its unique LYTAC platform, which aims to treat autoimmune diseases by destroying harmful proteins.

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

With late-stage veterans on board, MRM Health isn't just advancing a drug; it's building the strategic architecture for microbiome's leap from lab to market.

Tiziana Life Sciences has dosed the final patient in a key trial for its nasal MS drug, foralumab. With data imminent, this could be a breakthrough for an untreatable form of the disease.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.

Oblenio Bio's oversubscribed Series B will advance a novel tri-specific T-cell engager, aiming to reset the immune system without harsh side effects.

ProQR Therapeutics secures a crucial $59.2M, extending its runway and gaining a powerful endorsement from partner Eli Lilly for its Axiomer RNA editing platform.

ProQR's Axiomer platform achieves its first human validation, showing promise for rare pediatric liver diseases and signaling a major step for RNA editing.

Insmed and EMBARC's 3,000-patient study of brensocatib aims to do more than treat a chronic lung disease—it aims to fundamentally alter its course.

Passage Bio finds a lifeline in a reverse merger with Remix Therapeutics, a rising RNA star. But what does this deal truly mean for shareholders and the future of cancer treatment?

ARS Pharmaceuticals' needle-free allergy spray, neffy, faces a major setback with commercial insurers, forcing a strategic pivot toward fiscal discipline.

A small biotech reports its novel curcumin gel eases sickle cell pain. But its strategy of pre-approval access via pharmacies is a high-stakes economic gamble.

A clinical research firm is embedding 'patches of love' into its pediatric trials, asking if empathy can be as vital as data in treating sick children.

As LivaNova preps its Q2 2026 report, all eyes are on its growth in neuromodulation and cardiac care. Will innovation continue to drive its success?

A novel drug for glioblastoma enters a revolutionary trial, but the real story is the mission-driven company behind it, rewriting the rules of drug development.

Imbria's ninerafaxstat gains FDA Orphan Drug status for nHCM, a rare heart condition. This strategic win pits its unique metabolic approach against rivals.

Heparin, a trusted blood thinner, can trigger a fatal immune reaction. A small biotech's novel drug is now taking the global stage with a targeted solution.

A key FDA alignment for zervimesine not only de-risks a pivotal trial but signals a new era for treating the devastating psychosis of an overlooked dementia.

Ollin Biosciences secured $330M to challenge giants like Roche and Regeneron. Their next-gen antibody shows early promise in treating vision loss.

While investors grow weary of AI promises, Yidu Tech is turning a profit by building the unglamorous data infrastructure that makes real innovation possible.